Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01265953 · ClinicalTrials.gov registry record · NA

Chemoprevention of Prostate Cancer, HDAC Inhibition and DNA Methylation

A NA study of Prostate Cancer Prevention, sponsored by Portland VA Medical Center.

Completed
Registry status
NA
Development phase
98
Enrollment target
2
Study locations

NCT01265953 is a NA study of Prostate Cancer Prevention that has completed, run by Portland VA Medical Center. The registered enrollment target is 98 participants. The trial reports 2 study locations across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01265953, a NA study of Prostate Cancer Prevention, has completed, sponsored by Portland VA Medical Center.

COMPLETED
Registry status
NA
Development phase
98 participants
Enrollment target
2
Study locations

Study Summary

The objective of the study is to identify mechanisms by which compounds found in cruciferous vegetables alter gene expression via epigenetic modifications (changes in gene expression) and may prevent prostate cancer development. The investigators have found that sulforaphane (SFN), an isothiocyanate found in cruciferous vegetables, inhibits histone deacetylase (HDAC) activity in human colorectal and prostate cancer cells.

Conditions Studied

Interventions

  • DRUG SFN-rich broccoli sprout extract capsules
  • DIETARY_SUPPLEMENT Gelatin capsule containing microcrystalline cellulose.

Study Locations (2)

Oregon

  • OHSU Knight Cancer Institute - Portland
  • Portland VA Medical Center - Portland

Trial Details

FieldValue
Enrollment Target 98 participants
Start Date 2011-07
Est. Completion 2015-12
Phase NA

Sponsor

Portland VA Medical Center

15 total trials

What the Registry Record Tells You About NCT01265953

The ClinicalTrials.gov registry entry for NCT01265953 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 98 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Portland VA Medical Center, which has 15 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Prostate Cancer Prevention appearing as the primary indexed condition, and to 2 interventions - of which SFN-rich broccoli sprout extract capsules is the first listed.

NCT01265953 reports 2 study locations spanning 1 distinct geographic area - top geographies include Oregon.

Frequently Asked Questions

What is clinical trial NCT01265953 about?

NCT01265953 is a clinical study titled "Chemoprevention of Prostate Cancer, HDAC Inhibition and DNA Methylation". The objective of the study is to identify mechanisms by which compounds found in cruciferous vegetables alter gene expression via epigenetic modifications (changes in gene expression) and may prevent prostate cancer development. The investigators have found that sulforaphane (SFN), an isothiocyanat...

What is the current status of trial NCT01265953?

This trial is currently completed. It is a NA study. The enrollment target is 98 participants. The study started on 2011-07. Estimated completion is 2015-12.

What conditions does trial NCT01265953 study?

This clinical trial studies the following conditions: Prostate Cancer Prevention.

What interventions are being tested in trial NCT01265953?

The interventions under investigation include: SFN-rich broccoli sprout extract capsules (DRUG), Gelatin capsule containing microcrystalline cellulose. (DIETARY_SUPPLEMENT).

Who is sponsoring clinical trial NCT01265953?

This trial is sponsored by Portland VA Medical Center, which has 15 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01265953 being conducted?

This trial has 2 study locations across Oregon. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.